2025-07-11 - Analysis Report
Okay, here's a report analyzing Transmedics Group Inc (TMDX) based on the provided data.

## Transmedics Group Inc (TMDX) Stock Analysis Report

**Ticker:** TMDX
**Company Name:** Transmedics Group Inc
**Description:** Transmedics Group Inc. is a medical technology company revolutionizing organ transplantation with its Organ Care System (OCS).

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 239.15%
*   **VOO (S&P 500) Cumulative Return:** 67.73%
*   **Absolute Divergence:** 173.3 (TMDX outperformed VOO by 173.3 percentage points)
*   **Relative Divergence:** 65.9 (TMDX's current divergence is at the 65.9th percentile of its historical divergence range).
*   **Divergence Range:** Max: 296.4, Min: -64.2

**Analysis:** TMDX has significantly outperformed the S&P 500. The large absolute divergence indicates strong relative performance. The relative divergence of 65.9 suggests that while the outperformance is substantial, it is not at its historical peak, leaving room for potential further gains or mean reversion.

### 2. Alpha, Beta Analysis

Here's a table summarizing the alpha and beta analysis:

| Year       | CAGR     | MDD      | Alpha   | Beta | Cap(B) |
| ---------- | -------- | -------- | ------- | ---- | ------ |
| 2019-2021  | -4.0%   | 63.4%   | -52.0% | 0.0  | 0.7   |
| 2020-2022  | 140.0%  | 68.3%   | 138.0% | 0.1  | 2.1   |
| 2021-2023  | 95.0%   | 69.4%   | 77.0%  | 0.2  | 2.7   |
| 2022-2024  | 147.0%  | 82.8%   | 121.0% | 0.2  | 2.1   |
| 2023-2025  | 120.0%  | 82.8%   | 72.0%  | 0.5  | 4.2   |

**Analysis:**

*   **CAGR:** Shows impressive growth over the periods, especially from 2020 onwards.
*   **MDD (Maximum Drawdown):** High MDD values indicate significant volatility and risk.
*   **Alpha:** Consistently positive and high, demonstrating strong outperformance relative to the market.
*   **Beta:**  Generally low, suggesting the stock is less sensitive to market movements than the S&P 500 (although Beta is increasing).  The Beta from 2023-2025 is notably higher at 0.5, suggesting increased correlation with the market in the recent period.
*   **Cap(B):** Market capitalization of the company in Billions.

### 3. Recent Price Movement

*   **Current Price:** 124.78
*   **Previous Close:** 126.41
*   **Price Change:** -1.29
*   **5-day Moving Average:** 126.235
*   **20-day Moving Average:** 131.388
*   **60-day Moving Average:** 117.4512

**Analysis:** The current price is below both the 5-day and 20-day moving averages, suggesting a short-term downtrend. The price decrease of -1.29 from the previous close, while not massive, indicates a slight negative movement.

### 4. Market Risk Indicators

*   **Market Risk Indicator (MRI):** 0.3373 (Low Risk)
*   **RSI:** 51.16
*   **PPO:** -1.29
*   **Hybrid Signal:** cash_69%_Sell 0.7% of holdings (4 shares - Caution - MRI:0.35) (Cash Ratio: 69% on 2025-06-16)
*   **Delta_Previous_Relative_Divergence (20-day):** -2.8 (Negative - indicating a short-term decline in relative performance)
*   **Expected Return (%):** 52.1 (Projected excess return over S&P 500 with long-term dollar-cost averaging)

**Analysis:**

*   The MRI indicates a **low-risk** environment.
*   The RSI of 51.16 is neutral, suggesting neither overbought nor oversold conditions.
*   The negative PPO suggests a short-term downtrend.
*   The Hybrid Signal recommends a cautious approach, suggesting selling a small portion of holdings and maintaining a high cash position.
*   The negative Delta_Previous_Relative_Divergence confirms the recent underperformance relative to the S&P 500.
*   The Expected Return of 52.1% is very promising, indicating significant potential for long-term outperformance through regular investment.
*   The recent price change (-1.29) and negative Delta_Previous_Relative_Divergence (-2.8) support a short-term downtrend view.

### 5. Recent News & Significant Events

*   **2025-07-10:** Major business developments, regulatory changes, or market events.
*   **2025-07-09:** Analyst discussions on recent performance and outlook, considering industry and economic factors.
*   **2025-07-08:** Stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-07-11:** Market experts highlighting risks and opportunities; advice to monitor news and announcements.

**Analysis:** Recent news indicates potential significant events and market volatility impacting the stock. Investors should closely monitor company announcements and news releases for further developments. The analyst discussions and expert opinions should be considered carefully.

### 6. Recent Earnings Analysis

| 날짜       | EPS  | 예상 EPS |
| ---------- | ---- | -------- |
| 2025-05-08 | 0.7  | 0.29     |
| 2025-02-27 | 0.19 | 0.22     |
| 2024-10-28 | 0.12 | 0.29     |
| 2024-07-31 | 0.35 | 0.21     |
| 2024-04-30 | 0.35 | 0.03256  |

**Analysis:** TMDX has exceeded EPS expectations in the most recent quarter (2025-05-08). While some previous quarters showed misses (2024-10-28), the overall trend indicates positive earnings surprises.

### 7. Financial Information: Revenue and Profitability

| Quarter    | Revenue  | Profit Margin |
| ---------- | -------- | ------------- |
| 2025-03-31 | $0.14B | 61.47%        |
| 2024-12-31 | $0.12B | 59.21%        |
| 2024-09-30 | $0.11B | 55.94%        |
| 2024-06-30 | $0.11B | 60.59%        |
| 2024-03-31 | $0.10B | 61.91%        |

**Analysis:** Revenue is steadily increasing, indicating growth. High profit margins suggest efficient operations and a strong pricing strategy.

### 8. Financial Information: Capital and Profitability

| Quarter    | Equity   | ROE     |
| ---------- | -------- | ------- |
| 2025-03-31 | $0.27B | 9.64%  |
| 2024-12-31 | $0.23B | 3.00%   |
| 2024-09-30 | $0.21B | 2.01%   |
| 2024-06-30 | $0.19B | 6.42%   |
| 2024-03-31 | $0.16B | 7.65%   |

**Analysis:** Equity is increasing, suggesting financial strength. ROE is volatile but generally positive, indicating good profitability relative to equity. The significant increase in ROE in the most recent quarter is a positive sign.

### 9. Overall Analysis

Transmedics Group Inc (TMDX) has demonstrated significant outperformance relative to the S&P 500. The company exhibits high growth, strong profitability, and positive earnings surprises. However, the high maximum drawdown indicates significant volatility. Recent news suggests potential market events impacting the stock, requiring careful monitoring. The hybrid signal recommendation of selling a small portion of holdings and maintaining a high cash position reflects a cautious approach. Given the strong expected return, long-term dollar-cost averaging may be a suitable strategy.
